Abstract: The present disclosure relates to compounds and methods for modulating the expression of fxn, and treating diseases and conditions in which fxn plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a trinucleotide repeat sequence GAA; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence GAA; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.

Abstract: A display panel and an electronic terminal are provided, including a plurality of opening areas, an array substrate, a color filter substrate positioned opposite to the array substrate, a backlight module arranged on one side of the array substrate away from the color filter substrate; and an optical layer disposed in at least one of the color filter substrate and the array substrate. The color filter substrate includes color resist portions in the respective opening areas. The optical layer is configured to converge light and is arranged corresponding to the color resist portions.

Abstract: The present disclosure provides a multifunctional climbing operation platform and an operation method thereof. The multifunctional climbing operation platform includes a main machine, clamping devices, a bolt retightening device, and an auxiliary sleeve replacement box, wherein the clamping devices each include: a fixed seat; and a pair of claw bars swingably arranged on the fixed seat and each including a rear bar body and a front bar body hinged together, wherein when the pair of claw bars are opened, an inner angle between the rear bar body and the front bar body is greater than 180°, the main machine and the clamping devices can climb along an object to be climbed, the bolt retightening device can replace different sleeves from the auxiliary sleeve replacement box, and can screw a bolt on the object. The present disclosure has the advantages of a large avoidance range and diverse functions.

Abstract: An automatic support device for resisting rock burst in mines is provided, which includes bases symmetrically distributed, sliding frames are slidably connected to the bases, hydraulic rods are fixedly connected to the bases, and telescopic ends of the hydraulic rods are fixedly connected to the adjacent sliding frames. The sliding frames are fixedly connected to brackets, and the brackets symmetrically distributed are provided with a main support plate, on which pushing rods are provided. The device can slow down the impact force of the device when rock burst occurs in the mine, at the same time, it plays a supporting role in the mine, ensuring the stability of the roof of the mine.

Abstract: An application method of Prevotella copri includes: applying the Prevotella copri in preventing and treating the ADHD. The Prevotella copri is applied in an effective therapeutic amount to achieve treating the ADHD, and a strain number of the Prevotella copri is JCM 13464=DSM 18205. It is indicated through animal experiments that the Prevotella copri can significantly improve hyperactive behavior, spontaneous activity levels and impulsive behavior hyperactivity. A further experimental exploration finds that the Prevotella copri can significantly increase levels of adrenocorticotropic hormone and cortisol in serum, improve neuroendocrine system dysfunction, and significantly increase gene expressions of glucocorticoid receptor (Nr3c1) and mineralocorticoid receptor (Nr3c2), thereby alleviating ADHD social dysfunction, which provides a theoretical basis for application prospects of probiotics in alleviating the ADHD.

Abstract: A remote-sensing yield estimation method is described that is applicable to a crop whole growth period and belongs to the field of data processing methods and photogrammetry technologies with prediction purpose. In the present disclosure, in combination with agricultural knowledge of crop yields and multi-source remote-sensing data, with the biomass estimation model of whole growth period, the biomass contribution rate curve and the crop harvest index as basis, a crop yield estimation model of whole growth period with stable spatiotemporal extensibility is constructed. The yield estimation model uses the relative accumulated temperature and the remote-sensing vegetation index as variable inputs. Further, based on genetic algorithm, the parameters of the model are optimized in a case of failing to directly construct the model with data fitting due to less sample points, so as to help solve the problems of poor spatiotemporal mobility of the yield estimation model.

Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.

Abstract: The disclosure relates to synthetic methods for producing polyamides, for example pyrrole and imidazole containing polyamides of Formula (I) or (II), or a pharmaceutically acceptable salts thereof. These polyamides bind genes having expanded oligonucleotide repeat sequences, which thereby modulates transcription. The disclosure further provides methods of modulation of the transcription of such DNA, and the use of polyamides as therapeutic agents to treat diseases associated with such DNA.

Abstract: The present invention relates to new methods of manufacturing benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), and intermediates thereof.

Abstract: The present disclosure relates to transcription modulator molecule compounds and methods for modulating the expression of dmpk, and treating diseases and conditions in which dmpk plays an active role. The transcription modulator comprising a) the first terminus comprising a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence CAG or CTG; b) a second terminus comprising a protein-binding moiety capable of binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence CAG or CTG; and c) an oligomeric backbone comprising a linker between the first terminus and the second terminus.

Abstract: The present disclosure relates to compounds and methods for modulating the expression of fxn, and treating diseases and conditions in which fxn plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a trinucleotide repeat sequence GAA; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence GAA; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.

Abstract: A compound of formula (I) or an optical isomer thereof, and pharmaceutically acceptable salts, prodrugs, aquo-complexes or non-aqueous-solvent complexes thereof are provided. Experiments prove that, compared with a control compound MGL-3196, the compound of formula (I), which is obtained through specific substitution sites and specific substitution types, is higher in agonist activity to THR-beta and significantly improved in selectivity on THR-beta/THR-alpha. The compound can be used in preparing THR-beta agonist and drugs for treating adaption diseases (including dyslipidemia, hypercholesteremia, non-alcoholic steatohepatitis and non-alcoholic fatty liver disease) applicable to the THR-beta agonist.

Abstract: The present disclosure relates to transcription modulator molecules having a first terminus, a second terminus, and an oligomeric backbone and methods for treating Huntington's disease.

Abstract: The present disclosure relates to compounds and methods for modulating the expression of fxn, and treating diseases and conditions in which fxn plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence CGG; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence CGG; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.

Abstract: The present disclosure relates to transcription modulator molecules having a first terminus, a second terminus, and an oligomeric backbone and methods for treating Huntington's disease.

Abstract: The disclosure is directed to deutetrabenazine analogs, compositions comprising same and methods of detecting same in compositions comprising deutetrabenazine.

Abstract: The present invention relates to new extended release pharmaceutical compositions and methods of use thereof for the treatment of disorders.

Abstract: The present disclosure relates to compounds and methods which may be useful for modulating the expression of a target gene comprising a CGG trinucleotide repeat sequence and treating diseases and conditions in which the target gene plays an active role. The present disclosure provides compounds and methods for modulating the expression of fmr1 and fmr2, and provides compounds and methods for treating fragile X syndrome and fragile XE syndrome.

Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.

Abstract: The present disclosure relates to compounds and methods for modulating the expression of dmpk, and treating diseases and conditions in which dmpk plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence CAG or CTG; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence CAG or CTG; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.